4.5 Article

Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression

期刊

出版社

OXFORD UNIV PRESS
DOI: 10.1017/S1461145711001088

关键词

Deep brain stimulation; subgenual cingulate gyrus; treatment-resistant depression

资金

  1. Fondo de Investigacion Sanitaria (FIS) [PI 06/0662, PS 09/00580]
  2. Instituto Carlos III
  3. Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) [P91G]
  4. VI Plan Nacional I + D + I
  5. CONSOLIDER, accion CIBER
  6. Spanish Ministry of Science and Innovation
  7. Instituto de Investigacion Carlos III
  8. European Regional Development Fund (ERDF)
  9. [SAF2007-62378]

向作者/读者索取更多资源

Deep brain stimulation (DBS) is currently tested as an experimental therapy for patients with treatment-resistant depression (TRD). Here we report on the short- and long-term (1 yr) clinical outcomes and tolerance of DBS in eight TRID patients. Electrodes were implanted bilaterally in the subgenual cingulate gyrus (SCG; Broadman areas 24-25), and stimulated at 135 Hz (90-mu s pulsewidth). Voltage and active electrode contacts were adjusted to maximize short-term responses. Clinical assessments included the 17-item Hamilton Depression Rating Scale (HAMD(17); primary measure), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) Scale. In the first week after surgery, response and remission (HAMD <= 7) rates were, respectively 87.5% and 50%. These early responses were followed by an overall worsening, with a response and remission rates of 37.5% (3/8) at 1 month. From then onwards, patients showed a progressive improvement, with response and remission rates of 87.5% and 37.5%, respectively, at 6 months. The corresponding figures at 1 yr were 62.5% and 50%, respectively. Clinical effects were seen in all HAMD subscales without a significant incidence of side-effects. Surgical procedure and post-operative period were well-tolerated for all patients. This is the second independent study on the use of DBS of the SCG to treat chronic depression resistant to current therapeutic strategies. DBS fully remitted 50% of the patients at 1 yr, supporting its validity as a new therapeutic strategy for TRD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据